SCHEMBL17256804

SCHEMBL17256804

CO/N=C(\C)c1sccc1C#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.38
RXFP1 Q9HBX9 1/20 0.38
KMT2A Q03164 7/20 0.37
MEN1 O00255 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KDM4E B2RXH2 3/20 0.34
GAA P10253 3/20 0.34
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4C Q9H3R0 1/20 0.34
HPGD P15428 3/20 0.33
LMNA P02545 1/20 0.33
RECQL P46063 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
BLM P54132 1/20 0.32
USP2 O75604 1/20 0.32
ALOX15 P16050 1/20 0.32
CASP7 P55210 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17256806 1.00 POLB (0.38) POLBRXFP1KMT2AMEN1SMN1; SMN2
SCHEMBL17257563 0.82 KMT2A (0.38) POLBRXFP1KMT2AMEN1SMN1; SMN2
SCHEMBL17256846 0.82 MEN1 (0.33) POLBRXFP1KMT2AMEN1SMN1; SMN2
SCHEMBL17257561 0.82 KMT2A (0.38) POLBRXFP1KMT2AMEN1SMN1; SMN2
SCHEMBL17256849 0.82 MEN1 (0.33) POLBRXFP1KMT2AMEN1SMN1; SMN2
SCHEMBL17257414 0.76 RAB9A (0.54) POLBKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL17257472 0.76 KMT2A (0.34) POLBKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL17257412 0.76 RAB9A (0.54) POLBKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL17257194 0.76 KMT2A (0.34) POLBKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL24577695 0.75 LMNA (0.39) POLBKMT2AMEN1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US claimed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US claimed
EP-3143055-B1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORP (JP) 2019-09-04 EP disclosed
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US disclosed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group PAM, PPOX, MB POLB 178/4885RXFP1 1123/4885KMT2A 2399/4885
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP PAM, PPOX, MB POLB 178/4885RXFP1 1123/4885KMT2A 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.